Naturmega’s biomimetic Ruby-O improves omega-3 delivery for heart health

New clinical research backs Naturmega’s next-generation omega-3 ingredient, Ruby-O Balance, demonstrating it helps to reduce triglycerides in non-medicated adults with moderate hypertriglyceridemia — having high levels of the harmful fats — at a lower daily dose compared to standard fish oil.

Inspired by how the human body naturally recognizes and integrates lipids, Ruby-O is based on a biomimetic design for omega-3 delivery. Naturmega claims this targets more efficient omega-3 delivery of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) at the cellular level.

Naturmega leveraged its patented BPL-O3TM (Bonded Phospholipid Omega-3) molecular platform to develop Ruby-O Balance. The ingredient is engineered with a bonded phospholipid architecture that more closely resembles lipid structures naturally present in human cell membranes.

“From the outset, we challenged ourselves to rethink omega-3 dosing. We wanted to prove that smarter delivery, not higher doses, could drive real clinical impact,” says Jorge Atencio, general manager of Naturmega. “Ruby-O’s BPL-O3 platform is proof of that vision.”

The findings align with growing evidence suggesting that omega-3 efficacy is not only associated with dose, but also with how lipids are structured, delivered, and utilized at the cellular level.

Breakthrough in cellular science

The randomized, double-blind clinical trial, published in BMC Complementary Medicine and Therapies, indicates that Ruby-O Balance supports broader cardiometabolic health pathways beyond triglyceride reduction.

The 12-week trial compared the Ruby-O Balance formula of 825 mg/day of EPA+DHA to a more conventional triglyceride-based fish oil delivering 903 mg/day of EPA+DHA.

Participants were adults with elevated triglyceride levels who were not receiving lipid-lowering medication, reflecting a real-life demographic commonly targeted by dietary omega-3 supplementation.

Ruby-O supported favorable trends in cardiometabolic biomarkers: blood pressure, glycemic control, waist-to-hip ratio, and inflammatory markers.

Despite the lower omega-3 dose, Ruby-O Balance achieved up to three times greater efficiency in lowering triglyceride levels compared to standard fish oil. Moreover, a higher share of participants using the supplement reached healthy triglyceride thresholds than on the conventional fish oil.

Meanwhile, the solution demonstrated that participants absorbed omega-3 more efficiently (34%), measured by the Omega-3 Index per mg of EPA+DHA, validating BPLO3’s bioavailability.

Ruby-O also supported favorable trends in cardiometabolic biomarkers: blood pressure, glycemic control, waist-to-hip ratio, and inflammatory markers.

Researchers noted a “mild but significant” increase in partial thromboplastin time — measuring how long blood takes to clot —  suggesting a potential antithrombotic effect for future exploration.

Next steps in clinical roadmap

Naturmega says the findings represent a foundational milestone in its expanding clinical roadmap for the Ruby-O platform. Subsequent clinical research will include larger patient populations, longer intervention periods, and a “deeper exploration of cardiovascular and metabolic outcomes.”

Ongoing and planned studies will further evaluate triglyceride responder profiles, extended cardiometabolic biomarkers, and the performance of Ruby-O across different formulation formats and health applications, according to the supplier.

The company plans to share additional data from these studies later this year.

“This study was never intended to stand alone,” says Wilson Martínez, R&D+i director at Naturmega.

“It is part of a deliberate scientific strategy to understand how bonded phospholipid omega-3s interact at the cellular level and how that interaction can translate into more consistent, real-world health benefits across populations, outcomes, and formulations.”

Beyond its clinical performance, Ruby-O’s versatile molecular architecture can co-deliver additional bioactives, supporting expanded applications across cardiovascular, metabolic, cognitive, prenatal, and performance-focused nutrition, highlights Naturmega.

In other omega-3 news this week, researchers found higher omega-3 blood levels were associated with reduced early-onset dementia risk, despite people’s genetics.

Global deficiencies are still significant, with authors of a separate paper flagging that 76% of the world’s population are not consuming sufficient omega-3s. Their analysis flags common confusion surrounding omega-3 recommendations, noting that guidelines typically differ by country.